Chongqing Lummy Pharmaceutical - Asset Resilience Ratio

Latest as of March 2024: -0.19%

Chongqing Lummy Pharmaceutical (300006) has an Asset Resilience Ratio of -0.19% as of March 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Chongqing Lummy Pharmaceutical (300006) total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

CN¥-5.53 Million
≈ $-809.13K USD Cash + Short-term Investments

Total Assets

CN¥2.98 Billion
≈ $435.55 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2007–2022)

This chart shows how Chongqing Lummy Pharmaceutical's Asset Resilience Ratio has changed over time. See Chongqing Lummy Pharmaceutical (300006) net assets for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Chongqing Lummy Pharmaceutical's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Chongqing Lummy Pharmaceutical (300006) total market value.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥-5.53 Million -0.19%
Total Liquid Assets CN¥-5.53 Million -0.19%

Asset Resilience Insights

  • Limited Liquidity: Chongqing Lummy Pharmaceutical maintains only -0.19% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Chongqing Lummy Pharmaceutical Industry Peers by Asset Resilience Ratio

Compare Chongqing Lummy Pharmaceutical's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
AbbVie Inc
NYSE:ABBV
Drug Manufacturers - General 0.02%
Roche Holding AG
SW:ROG
Drug Manufacturers - General 15.37%
Biogen Inc
NASDAQ:BIIB
Drug Manufacturers - General 2.74%
CSPC Pharmaceutical Group Limited
F:CVG
Drug Manufacturers - General 4.64%
AstraZeneca PLC
LSE:AZN
Drug Manufacturers - General 0.03%
Yifan Xinfu Pharmaceutical Co Ltd
SHE:002019
Drug Manufacturers - General 0.53%
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952
Drug Manufacturers - General 5.37%
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3
Drug Manufacturers - General 10.10%

Annual Asset Resilience Ratio for Chongqing Lummy Pharmaceutical (2007–2022)

The table below shows the annual Asset Resilience Ratio data for Chongqing Lummy Pharmaceutical.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2022-12-31 -0.29% CN¥-8.78 Million
≈ $-1.29 Million
CN¥3.05 Billion
≈ $447.04 Million
-0.09pp
2021-12-31 -0.20% CN¥-5.87 Million
≈ $-858.97K
CN¥2.93 Billion
≈ $428.28 Million
+0.15pp
2020-12-31 -0.35% CN¥-11.00 Million
≈ $-1.61 Million
CN¥3.15 Billion
≈ $460.62 Million
-0.01pp
2019-12-31 -0.34% CN¥-11.81 Million
≈ $-1.73 Million
CN¥3.50 Billion
≈ $512.37 Million
+0.03pp
2018-12-31 -0.37% CN¥-11.68 Million
≈ $-1.71 Million
CN¥3.14 Billion
≈ $459.59 Million
-0.42pp
2013-12-31 0.05% CN¥1.10 Million
≈ $160.96K
CN¥2.18 Billion
≈ $319.31 Million
-0.10pp
2010-12-31 0.15% CN¥1.33 Million
≈ $195.32K
CN¥884.01 Million
≈ $129.36 Million
-0.04pp
2009-12-31 0.19% CN¥1.27 Million
≈ $185.50K
CN¥653.63 Million
≈ $95.65 Million
-0.27pp
2008-12-31 0.46% CN¥1.23 Million
≈ $180.46K
CN¥268.56 Million
≈ $39.30 Million
-0.19pp
2007-12-31 0.65% CN¥1.40 Million
≈ $204.86K
CN¥214.69 Million
≈ $31.42 Million
--
pp = percentage points

About Chongqing Lummy Pharmaceutical

SHE:300006 China Drug Manufacturers - General
Market Cap
$987.34 Million
CN¥6.75 Billion CNY
Market Cap Rank
#9171 Global
#2465 in China
Share Price
CN¥6.39
Change (1 day)
-0.78%
52-Week Range
CN¥3.44 - CN¥6.52
All Time High
CN¥11.34
About

Chongqing Lummy Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products in China. It provides anti-tumor, anti-inflammatory, antibacterial, digestive, anti-virus, blood system, cardiovascular system, acid-base balance nutritional medicine, endocrine system drugs, tumor adjuvant medication, antifungal, and opioid receptor antagonists. Chon… Read more